Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

Heather H. Cheng(University of Washington), Roman Gulati(Fred Hutch Cancer Center), Arun Azad(BC Cancer Agency), Rosa Nadal(Johns Hopkins University), P. Twardowski(City Of Hope National Medical Center), Ulka N. Vaishampayan(Wayne State University), N. Agarwal(University of Utah), Elisabeth I. Heath(Wayne State University), Sumanta K. Pal(City Of Hope National Medical Center), H-t Rehman(Johns Hopkins University), Amanda Leiter(Tisch Hospital), Julia Batten(University of Utah), Bruce Montgomery(University of Washington), Matthew D. Galsky(Tisch Hospital), Emmanuel S. Antonarakis(Johns Hopkins University), Koren Morag N(BC Cancer Agency), Evan Y. Yu(University of Washington)
Prostate Cancer and Prostatic Diseases
January 20, 2015
Cited by 82Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis